Johnson & Johnson’s COVID-19 vaccine would cost less than 200 pesos

Johnson & Johnson’s COVID-19 Vaccine, Made by Pharmaceutical Janssen, Will Be Available by the Second Half of 2021

The pharmaceutical Janssen, owned by the American multinational Johnson & Johnson, plans to have a COVID-19 vaccine in the second semester of 2021, at a price of less than 10 dollars (202 Mexican pesos, approximately).

This was revealed this Thursday by the vice president of the Johnson & Johnson Executive Committee, Joaquín Duato, in a conference at the Health Sector Sector Meeting, organized by IESE Business School, with the collaboration of the consulting firm McKinsey & Company.

The study plans to guarantee the vaccine “sometime in the first or second half of 2021,” he declared.

The first clinical results from Pfizer and Moderna, with 95 percent efficacy, are figures that represent “good omens” for the rest of the pharmaceutical companies focused on the same protein.

As reported by the Johnson & Johnson executive, the pharmaceutical company has worked in the supply chain to be able to offer billion vaccines in 2021 through a collaborative network.

“During the next six months there will be good news, we will be able to see how these effective vaccines will be available to the public”, emphasized Duato, who took the opportunity to emphasize that the vaccine in which his team works will also guarantee “the announced quality and safety standards” by other companies in the sector.

Production of vaccine. Photo from .

The speaker applauded the collaboration between partners in the pharmaceutical industry to find a vaccine: “It is not a competitive situation, it is a social issue and a global crisis in which we will need several vaccines, not just one, because we must vaccinate millions of people” .

To guarantee the vaccination of the population, Johnson & Johnson works together with governments on access and distribution plans, as is the case of COVAX, a project to which 500 million doses of its production will be destined for the lowest-income countries.

From the multinational they assure that the price will not focus on profit: “We will seek to guarantee access to the vaccine in all territories, the price will not be more than 10 dollars per vaccine.”

With information from .